Immuno AG

ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development

Retrieved on: 
Tuesday, September 19, 2023
Process, Change, University, Therapy, Senior, CMC, Cancer, Immuno AG, MBA, Research, University residence hall network, Doctor of Philosophy, HSG, Molecular Partners, Novartis, Biology, FDA, Technical, Inflammation, Pharmaceutical industry, Vaccine, Tisagenlecleucel, MD

In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.

Key Points: 
  • In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.
  • We are excited to have her join the team and lead our CMC and technical development efforts to develop and manufacture novel protein- and antibody-based therapies," said Steve Coats, PhD, Chief Development Officer at ImmunOs.
  • Her breadth and depth of expertise in technical development, manufacturing and operations will be important for advancing our first-in-class pipeline of multi-functional immunotherapies to and through clinical development."
  • "I believe that ImmunOs´ expertise in pioneering HLA-based therapeutics focusing on both oncology and immunology, led by IOS-1002, ImmunOs´ lead clinical candidate in oncology, is at the forefront of current research," said Dr. Constanze Guenther, Senior Vice President, CMC and Technical Development at ImmunOs.

ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board

Retrieved on: 
Tuesday, April 25, 2023
Oncology, Therapy, HLA, Stanford University, Cancer, Coronavirus Scientific Advisory Board, Immuno AG, Immunotherapy, Doctor of Philosophy, Associate, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial, University, Michael J. Curran, Immune system, FDA, Pharmaceutical industry, Vaccine, MD

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD , has been appointed Chairman of the Company´s Scientific Advisory Board.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD , has been appointed Chairman of the Company´s Scientific Advisory Board.
  • In addition to Dr. Curran, Taha Merghoub, PhD, Ulf Petrausch, MD, and Paul Bowness, MD, PhD, currently serve as Scientific Advisors to ImmunOs.
  • "We are proud to have Mike Curran chair our Scientific Advisory Board to support the development of our pipeline programs in both immuno-oncology and autoimmune diseases," said Sean R. Smith, Chief Executive Officer at ImmunOs.
  • "I am excited to help ImmunOs advance their first-in-class therapeutics, including the lead oncology program, IOS-1002, which targets multiple myeloid checkpoints," said Dr. Curran.

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

Retrieved on: 
Wednesday, April 12, 2023
Immortalised cell line, Cancer, Partnership, Immuno AG, Therapy, Orientation, Pharmaceutical industry

Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer.

Key Points: 
  • Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer.
  • ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
  • "We at ImmunOs are very satisfied with the work done by ProBioGen.
  • The tireless effort of the ProBioGen team has enabled ImmunOs to start clinical development as planned and to meet our milestones," said Jeff Abbey, Chief Operating Officer of ImmunOs Therapeutics.

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

Retrieved on: 
Tuesday, October 4, 2022
Company, Cancer, Oncology, BS, Cedars-Sinai Medical Center, Santa Clara University, KRAS, HLA, Nasdaq, University, Therapy, Bristol Myers Squibb, Eli Lilly and Company, Merck Serono, Wendell Pritchett, Onyx Pharmaceuticals, Internal medicine, MBA, Antibody, Synthetic biology, Cytokine, Immune system, Merck, Eli Lilly, Patient, Mathematics, Merck Group, Compugen (Israeli company), Degenerative disease, Board of directors, Lightspeed Venture Partners, KIR, Immuno AG, Board, Sanofi, Amgen, Wharton School of the University of Pennsylvania, Pharmaceutical industry, Vaccine, Biology, MD

Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics.

Key Points: 
  • Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics.
  • "We are delighted to welcome Joe Leveque to our Board of Directors," said Sean R. Smith, Chief Executive Officer at ImmunOs Therapeutics.
  • "I am impressed by ImmunOs unique approach of developing HLA-based immune-modulating agents," said Joseph Leveque, MD, member of ImmunOs Therapeutics Board of Directors.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.

Gimv strengthens its position in life sciences venture capital with the creation of a new dedicated platform

Retrieved on: 
Wednesday, June 15, 2022
Ablynx, Solution, List of life sciences, City, Drug development, Health care, VC, Pittsburgh Life Sciences Greenhouse, Euronext, Partner, Ecosystem, Consumer-driven healthcare, Investment, Immuno AG, Consumer, Patient, Johnson & Johnson, Fine chemical, Pharmaceutical industry, Video game, Gimv, Ambition

After solid growth within Gimvs existing Healthcare platform, a dedicated Life Sciences platform will strengthen the role of Gimv in the international life science VC ecosystem.

Key Points: 
  • After solid growth within Gimvs existing Healthcare platform, a dedicated Life Sciences platform will strengthen the role of Gimv in the international life science VC ecosystem.
  • The Life Sciences platform builds on the success and excellent returns generated by portfolio companies over four decades, including companies like Ablynx, where Gimv was a founding investor and Covagen, which was acquired by Johnson & Johnson.
  • Bram Vanparys*, Managing Partner and Head of Life Sciences at Gimv, said: The launch of the new Life Sciences platform represents an exciting next step for Gimv in the sector.
  • Having a VC centered Life Sciences platform separate from a PE centered Healthcare platform allows more focus for both teams while preserving potential synergies.

ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board

Retrieved on: 
Wednesday, September 1, 2021
Newton, University, PD-1, Economics, University of Melbourne, Oncology, German Cancer Research Center, University of Oxford, Department, Molecular imaging, La Trobe University, Virology, Monash University, CD47, Therapy, PD-L1, Nuffield Orthopaedic Centre, Rheumatology, National Center for Advancing Translational Sciences, DKFZ, Doctor of Philosophy, Clinical trial, IPO, CEO, Business administration, Program, Olivia, Antibody, Business development, Immunotherapy, MBA, Coronavirus Scientific Advisory Board (Turkey), Degenerative disease, NASDAQ, COO, Nuffield Department of Population Health, Company, Brain Tumour Research, Growth, Cancer, JD, University Hospital Heidelberg, Immuno AG, Â, Neoplasm, NCT, Kidney cancer, Pharmaceutical industry, Management

September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.

Key Points: 
  • September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.
  • Under Mr. Abbeys leadership, Argos Therapeutics successfully completed an IPO on NASDAQ, as well as a pivotal Phase 3 clinical trial in kidney cancer.
  • I am looking forward to working with the team at ImmunOs and its advisory boards, said Jeffrey Abbey, MBA, JD, COO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses.